Owing to the development of multiple novel therapies, there has been major progress in the
treatment of advanced prostate cancer over the last two decades; however, the disease …

The discovery of androgen dependence in prostate cancer in 1941 by Huggins and
colleagues has remained the backbone for the treatment of this disease. However, although …

Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to
the pathophysiology of prostate cancer. Despite successful translational efforts in targeting …

Simple Summary Early-stage and castration-sensitive prostate cancer (PCa) growth is solely
mediated by androgen signaling pathways. AR signaling inhibitors (ARSIs) have …

Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial
diagnosis; hence, androgen ablation therapy directed toward a reduction in serum …

The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer.
Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has …

Prostate cancer is the mostly commonly diagnosed non-cutaneous malignancy and the
second leading cause of cancer-related death affecting men in the United States. Moreover …

Despite the recent approval and widespread use of abiraterone acetate and enzalutamide
for the treatment of castration-resistant prostate cancer (CRPC), this disease still poses …

Prostate cancer is a hormone-dependent malignancy, whose onset and progression are
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …

The androgen receptor is a transcription factor and validated therapeutic target for prostate
cancer. Androgen deprivation therapy remains the gold standard treatment, but it is not …